A new study measured the results of including drug prices in DTC ads.
For the high-priced drug, the price disclosure significantly reduced the likelihood of participants asking their physician about the drug, asking their insurer about the drug, researching the drug online, and taking the drug.
However, results were significantly mitigated when a modifier was included about out-of-pocket costs.
A study showing that one in four insulin-treated patients surveyed at an urban US diabetes center were found to be cutting back on insulin use because of cost has been published.
The survey results also reveal that cost-related insulin underuse was associated with worse glycemic control and that more than a third of patients did not discuss the insulin underuse with their clinicians.
Of those who completed the survey, 25.5% (51) reported cost-related insulin underuse.
The S&P 500 healthcare sector has been on a tear in recent months, on track for its best quarter in five years and surging to an all-time high on Friday.
A forensic accounting of available financial data of the pharmaceutical giants Johnson & Johnson, Pfizer, Merck Sharp & Dohme, and Abbott—shows that from 2013 to 2015, these four multinational drug makers collectively avoided paying about $3.7 billion in taxes.
Publishing in JAMA Internal Medicine the median estimated cost of the full range of studies: $19 million to get new drug approval.
Pharma’s primary customer continues to be Wall Street.